Definitive Contract 75D30119C05670
Award Date
7/10/19
Potential Completion Date
6/30/21
Potential Value
$1.9M
Federal Agency
CDC Pittsburgh
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Available for Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Nashville, TN 37232, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services Centers for Disease Control and Prevention awarded a $4.8 million definitive contract to Vanderbilt University Medical Center to conduct research titled "Innovative Methods to Evaluate the Role of Influenza Vaccines in Attenuating Severe Disease in Adults." The prime contractor will lead a network of 16 academic medical centers as subcontractors to study the effectiveness of influenza vaccines in preventing critical illness. This award was...
This is a $13,460,835.60 delivery order awarded by the Department of Health and Human Services Centers for Disease Control and Prevention to Vanderbilt University Medical Center. The contract is for an Adult Inpatient and Outpatient VE Case Control Study, which will evaluate the effectiveness of COVID-19 and influenza vaccines. This order falls under the larger Safety and Healthcare Epidemiology Prevention Research Development 2016 (SHEPheRD 2016) indefinite delivery/indefinite quantity...
Vanderbilt University Medical Center was awarded a definitive cost-plus-fixed-fee contract valued at $14,222,774.34 by the Centers for Disease Control and Prevention under funding opportunity announcement topic 9.3. The prime contractor will lead a network of subcontractors to conduct a prospective cohort study to assess the effectiveness of COVID-19 and influenza vaccines in preventing virus transmission within households. Major subcontractors include the Universities of Arizona, Emory,...
The Department of Health and Human Services Centers for Disease Control and Prevention awarded a $49,995,944 definitive cost-no-fee contract to Vanderbilt University Medical Center for Surveillance of Acutely Ill Adults with Respiratory Viruses, Including SARS-CoV-2. Vanderbilt University Medical Center will serve as the prime contractor and has subcontracted portions of the work to 26 other institutions, including The Cleveland Clinic Foundation, University of Utah, Beth Israel Deaconess...
This firm fixed price contract from the Centers for Disease Control and Prevention (CDC) to Vanderbilt University Medical Center (VUMC) evaluates the effectiveness of vaccines against COVID-19, influenza, and respiratory syncytial virus (RSV) among U.S. adults with severe acute respiratory illness. The $11,908,903.84 potential value contract monitors effectiveness against COVID-19, influenza, and emerging variants, as well as duration of protection. It also conducts RSV surveillance and builds...
This federal contract award was issued by the Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases to Vanderbilt University Medical Center (VUMC) to conduct a Phase II vaccine trial for Influenza H7N9. The contract has a total potential value of $4,033,051 and a completion date of May 31, 2021. This award is part of the Vaccine and Treatment Evaluation Units (VTEU) program, a major program focused on vaccine development and...
This is a prime contract award from the Centers for Disease Control and Prevention (CDC) to Vanderbilt University Medical Center (VUMC), a leading academic medical center and nonprofit healthcare provider. The $33,581,705.97 fixed-price contract, awarded under the CDC's Fiscal Year 2021 Broad Agency Announcement, supports VUMC's research on topics related to Topic 9.1. The contract has no set-aside designation. VUMC is a major recipient of federal funding and has extensive experience managing...
This is a federal contract award made by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Vanderbilt University Medical Center (VUMC). The contract is a Delivery Order issued under the Vaccine and Treatment Evaluation Units (VTEU) Indefinite Delivery Contract, with a ceiling value of $113,466.31 and a period of performance from September 15, 2015 to September 14, 2016. The contract is for task area D, sub-studies for...
This is a federal contract award to The Vanderbilt University, a private research university, by the Department of Health and Human Services Centers for Disease Control and Prevention (CDC) for CLINICAL EVALUATION LEAD SITE services. The $4,879,802.00 contract is a Delivery Order under the larger Clinical Immunization Safety Assessment (CISA) contract vehicle. The award does not have a set-aside designation. As the prime contractor, Vanderbilt University will provide critical research and...
This is a $12,797,150.73 Definitive Contract awarded by the Centers for Disease Control and Prevention (CDC) to Vanderbilt University Medical Center (VUMC), a major academic medical center and nonprofit healthcare provider, for a new network of household transmission studies to evaluate vaccine effectiveness. The contract has a performance period ending on March 28, 2025 and utilizes a Firm Fixed Price pricing arrangement. VUMC is serving as the prime contractor and has awarded subcontracts to...